A descoberta de que a expansão da repetição do hexanucleotídeo GGGGCC no gene C9ORF72 é uma das principais causas da Demência Frontotemporal (DFT) e da Esclerose Lateral Amiotrófica (ELA) foi um importante avanço para o entendimento dessas doenças. Essa mutação é responsável por grande parte dos casos hereditários e esporádicos. O indivíduo acometido pode se manifestar clinicamente como ELA, DFT e como a combinação fenotípica ELA-DFT. No entanto, vários outros fenótipos clínicos já foram descritos, como o de doenças que cursam com parkinsonismo atípico, ou mesmo formas que se assemelham à Doença de Parkinson e à Doença de Alzheimer. O objetivo do trabalho foi fazer uma revisão dos fenótipos associados à mutação do gene C9ORF72 descritos na literatura e descrever os casos associados à mutação identificados nos ambulatórios do Hospital das Clínicas de Ribeirão Preto (HCRP). A revisão foi feita a partir de artigos publicados entre 2011 e 2014, buscados na base de dados eletrônica PubMed. Foram selecionados 99 artigos em inglês, em que a mutação do gene C9ORF72 foi objetivo de estudo e, a partir destes, foram selecionados 44 artigos que apresentavam uma descrição individualizada dos fenótipos de um total de 219 pacientes. Nessa revisão, foram identificados 31 fenótipos. No HCRP, os pacientes com sintomas sugestivos eram encaminhados para coleta de sangue após consentimento informado. A extração do DNA a partir do material fornecido pelos pacientes foi realizada no Centro de Medicina Genômica do HCRP de forma automatizada e a amplificação dos fragmentos de interesse foi obtida pela reação de cadeia em polimerase (PCR) e pelo método qualitativo Repeat-Primed PCR (RPPCR). Foram identificados 17 pacientes com a mutação e as manifestações clínicas desses pacientes foram descritas. Foram identificados 6 fenótipos, dentre eles ELA, ELA-DFT, variante comportamental da DFT, Afasia Progressiva associada à ELA, Esquizofrenia e Esclerose Lateral Primária. Conclui-se que a variabilidade da apresentação clínica incial dos indivíduos com a mutação é extensa. Ainda não se sabe o que faz com que a mutação se manifeste de uma forma ou de outra. Saber o real tamanho da expansão do gene que causa essas doenças e ter um maior conhecimento sobre a penetrância do gene são fundamentais para aconselhamento genético das famílias acometidas. / Hexanucleotide repeat expansion GGGGCC in the C9ORF72 gene is one of the main causes of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) being an important step towards the understanding of these disorders. This mutation is responsible for much of hereditary and sporadic cases. The affected subject may manifest ALS, FTD and ALS-FTD phenotype. However, several other clinical phenotypes have been described as atypical parkinsonism or forms that resemble Parkinson\'s disease and even Alzheimer\'s disease. The objective was to review phenotypes associated with C9ORF72 mutation described in literature and describe cases associated with the mutation identified in outpatient clinics of the Hospital das Clínicas de Ribeirão Preto (HCRP). The review was made from articles published between 2011 and 2014 searched on electronic database PubMed. We selected 99 papers in English in which mutation of the gene C9ORF72 was analyzed, and 44 were selected. We described phenotypes of 219 patients. We found 31 different phenotypes. In HCRP, patients with suggestive symptoms were selected to collect blood after informed consent. DNA extraction from the blood was done by an automated way in Genomic Medical Center in HCRP. Amplification of fragments of interest was obtained by polymerase chain reaction (PCR) and the qualitative method Repeat-primed PCR (RP-PCR). We identified 17 patients with mutation and their clinical manifestations were described. Six phenotypes were described including ALS, ALS-FTD, behavioral variant FTD, progressive aphasia associated with ALS, schizophrenia and Primary Lateral Sclerosis. We conclude variability of initial clinical presentation of patients with mutation is extensive. It is not known why this mutation manifests itself in different ways. Its important to understand how repeat expansion size causes distinct diseases, and to achieve a greater knowledge of the gene penetrance for genetic counseling of affected families.

The discovery that the (GGGCC)n>30 repeat expansion in the non-coding region of C9orf72 (C9) is the most prevalent mutation in familial and sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has led to a massive effort to discover the mechanism by which the expansion causes ALS. One effect of the repeat expansion is the reduction in C9 mRNA and protein levels. Therefore, we chose to concentrate on studying the function of C9 and how its reduction contributes to ALS progression. First, we show that C9 short (C9S) and long (C9L) isoforms have different cellular localization, and that C9 knockdown in several cell lines, results in significant changes in gene expression. Specifically, we show that differentially expressed genes were enriched in immune system activation pathway. Additionally, we observed gene expression changes in important glutamate-glutamine cycling genes and show that C9 knockdown results in accumulation of intracellular glutamate. We also show that C9S isoform may regulate gene expression as it interacts with chromatin, and can be ChIPed on the promoter of endothelin-1 (EDN1). C9 knockdown also leads to significant morphological changes that include increased cell sizes and nucleus, massive vacuolization, and results in reduced cell viability. Investigation into the vacuoles revealed that they originate from hyperactivation of macropinocytosis. The hyperactivation of macropinocytosis results in a caspase-independent cell death known as methuosis. We show that vacuolization is a p53-dependent process, and we present evidence that p53 mediates vacuolization via the repression of the mevalonate pathway. Furthermore, we found that inhibition of isoprenylation, a process depending on mevalonate pathway products (geranylgeranyl pyrophosphate and farnesyl pyrophosphate), participates in the induction of vacuoles. Importantly, we also reveal that C9 knockdown leads to mitochondrial dysfunction, increased ROS, increased DNA-damage and p53 activation, all of which are seen in C9 ALS patient samples or in C9 patient derived motor neurons (C9 iMNs). Our results reveal several previously unknown pathways which are affected by C9 knockdown , which have potential therapeutic implications, that include endothelin signaling and macropinocytosis, both of which can be blocked with FDA approved drugs.

The aim of this thesis was to identify genetic factors involved in frontotemporal lobar degeneration (FTLD), a neurodegenerative disorder clinically characterised by a progressive change in personality, behaviour and language. FTLD is a genetically complex disorder and a positive family history is found in up to 40% of the cases. In 10-20% of the familial cases the disease can be explained by mutations in the gene encoding the microtubule associated protein tau (MAPT). In the first study we describe the clinical and neuropathological features of a Finnish family with FTLD caused by a mutation in MAPT. We also provide evidence that the pathogenic mechanism of this mutation is through altered splicing of MAPT transcripts. Recently, mutations in the gene encoding progranulin (PGRN) were identified as a major cause of FTLD. In the second study we describe a Swedish family with FTLD caused by a frameshift mutation in PGRN. We provide a clinical and neuropathological description of the family, as well as evidence that the pathogenicity of this mutation is through nonsense-mediated decay of the mutant mRNA transcripts and PGRN haploinsufficiency. In the third study we describe a novel PGRN splice site mutation and a previously described PGRN frameshift mutation, found in a mutation screen of 51 FTLD patients. We describe the clinical and neuropathological characteristics of the mutation carriers and demonstrate that haploinsufficiency is the pathogenic mechanism of the two mutations. In the fourth study we investigate the prevalence of PGRN and MAPT gene dosage alterations in 39 patients with FTLD. No gene dosage alterations were identified, indicating that variations in copy number of the PGRN and MAPT genes are not a common cause of disease, at least not in this FTLD patient collection.

Patients with Amyotrophic lateral sclerosis (ALS) often experience cognitive impairment that accompanies degeneration of the motor system. A valuable tool for assessing cognitive control over behaviour is the antisaccade task which requires: 1) inhibition of the automatic response to look towards an eccentric visual stimulus (prosaccade) to instead 2) redirect gaze in the opposite direction of the stimulus (antisaccade). Psychometric tests were used to quantify the degree of impairment, while eye tracking, functional magnetic resonance imaging (fMRI) and structural MRI were combined to identify the neural correlates of cognitive impairment in ALS. We predict ALS patients will have executive dysfunction and grey matter loss in executive and oculomotor control areas that will affect antisaccade performance and will alter the corresponding brain activation. ALS patients and age-matched controls participated in a rapid-event-related fMRI design with interleaved pro- and antisaccade trials. Catch trials (no stimulus presented after instructional cue to prepare pro- or antisaccade) allowed us to discern the preparatory period from the execution period. ALS patients were biased towards automatic saccade responses, and had greater difficulty with antisaccades relative to controls in terms of correct and timely responses. We found that worsened antisaccade performance in ALS correlated with the degree of cognitive impairment. Generally, we found trends of increased brain activation during the preparatory period of antisaccades in ALS patients compared to controls in most oculomotor areas; meanwhile few differences were seen during execution. Structural analyses revealed ALS patients had decreased grey matter thickness in frontotemporal and oculomotor regions such as the frontal and supplementary eye fields (FEF, SEF) and the dorsolateral prefrontal cortex (DLPFC). These findings suggest that loss of structural integrity and executive dysfunction may elicit compensation mechanisms to improve functional and behavioural performance. Despite this compensation, ALS patients still performed worse on antisaccades than controls. Further investigation to expand the current data set should improve our ability to assuredly identify the neural correlates of cognitive decline in ALS, and may provide a model system to use for critical evaluation of future therapies and interventions for ALS. / Thesis (Master, Neuroscience Studies) -- Queen's University, 2011-09-22 14:20:39.704

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2010.

A hexanucleotide repeat expansion in the C9orf72 gene is the most common cause of familial amyotrophic lateral sclerosis and frontotemporal dementia. Genetic testing for this pathogenic mutation is challenging due to its GC rich, repetitive nature. I developed PCR based assays to detect the presence of the pathogenic variant, which were used in screening an archival cohort of Scottish ALS patients, and have also been implemented within a diagnostic setting. These PCR assays allow amplification of larger repeat expansions than have previously been reported, and can determine whether a C9orf72 expansion of greater than 100 repeats is present or not. It is not well understood how the repeat expansion leads to disease, but several potential mechanisms have been hypothesised, including reduced expression, RNA toxicity and protein toxicity via dipeptide repeat proteins produced through repeat associated non-AUG translation. Motor neurons are an understandably well studied target in amyotrophic lateral sclerosis, however the role of glia, particularly oligodendrocytes, in the pathogenesis of the disease has recently been highlighted from studies on rodent models and post mortem tissue. To investigate the effect of the C9orf72 repeat expansion on oligodendrocytes, we have applied a differentiation protocol to hiPSCs with the expansion and controls, including an isogenic control which has been generated in the lab. There was no difference in the production of neuronal and glial cell types between these cell lines. I went on to look for evidence of the main proposed pathological mechanisms of C9orf72 repeat expansions: loss of function or gain of function through either RNA or protein toxicity. hiPSC derived oligodendrocytes from both carrier and control showed low expression of C9orf72 mRNA, and there was no difference due to the presence of a repeat expansion. Carrier hiPSC derived oligodendrocytes displayed sense RNA foci, which did not appear to have an effect on cellular morphology. The detection of dipeptide repeat proteins proved challenging, and the results were inconclusive as to their presence in hiPSC derived oligodendrocytes. I went on to show there was no evidence of mislocalisation of TDP-43 in C9orf72 carrier oligodendrocytes. Finally, the study showed similar levels of cell death in basal conditions in carrier and control cells, and no clear difference in the response to endoplasmic reticulum stress. Further research will be required to elucidate the role of oligodendrocytes in C9orf72 related amyotrophic lateral sclerosis.

A descoberta de que a expansão da repetição do hexanucleotídeo GGGGCC no gene C9ORF72 é uma das principais causas da Demência Frontotemporal (DFT) e da Esclerose Lateral Amiotrófica (ELA) foi um importante avanço para o entendimento dessas doenças. Essa mutação é responsável por grande parte dos casos hereditários e esporádicos. O indivíduo acometido pode se manifestar clinicamente como ELA, DFT e como a combinação fenotípica ELA-DFT. No entanto, vários outros fenótipos clínicos já foram descritos, como o de doenças que cursam com parkinsonismo atípico, ou mesmo formas que se assemelham à Doença de Parkinson e à Doença de Alzheimer. O objetivo do trabalho foi fazer uma revisão dos fenótipos associados à mutação do gene C9ORF72 descritos na literatura e descrever os casos associados à mutação identificados nos ambulatórios do Hospital das Clínicas de Ribeirão Preto (HCRP). A revisão foi feita a partir de artigos publicados entre 2011 e 2014, buscados na base de dados eletrônica PubMed. Foram selecionados 99 artigos em inglês, em que a mutação do gene C9ORF72 foi objetivo de estudo e, a partir destes, foram selecionados 44 artigos que apresentavam uma descrição individualizada dos fenótipos de um total de 219 pacientes. Nessa revisão, foram identificados 31 fenótipos. No HCRP, os pacientes com sintomas sugestivos eram encaminhados para coleta de sangue após consentimento informado. A extração do DNA a partir do material fornecido pelos pacientes foi realizada no Centro de Medicina Genômica do HCRP de forma automatizada e a amplificação dos fragmentos de interesse foi obtida pela reação de cadeia em polimerase (PCR) e pelo método qualitativo Repeat-Primed PCR (RPPCR). Foram identificados 17 pacientes com a mutação e as manifestações clínicas desses pacientes foram descritas. Foram identificados 6 fenótipos, dentre eles ELA, ELA-DFT, variante comportamental da DFT, Afasia Progressiva associada à ELA, Esquizofrenia e Esclerose Lateral Primária. Conclui-se que a variabilidade da apresentação clínica incial dos indivíduos com a mutação é extensa. Ainda não se sabe o que faz com que a mutação se manifeste de uma forma ou de outra. Saber o real tamanho da expansão do gene que causa essas doenças e ter um maior conhecimento sobre a penetrância do gene são fundamentais para aconselhamento genético das famílias acometidas. / Hexanucleotide repeat expansion GGGGCC in the C9ORF72 gene is one of the main causes of Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) being an important step towards the understanding of these disorders. This mutation is responsible for much of hereditary and sporadic cases. The affected subject may manifest ALS, FTD and ALS-FTD phenotype. However, several other clinical phenotypes have been described as atypical parkinsonism or forms that resemble Parkinson\'s disease and even Alzheimer\'s disease. The objective was to review phenotypes associated with C9ORF72 mutation described in literature and describe cases associated with the mutation identified in outpatient clinics of the Hospital das Clínicas de Ribeirão Preto (HCRP). The review was made from articles published between 2011 and 2014 searched on electronic database PubMed. We selected 99 papers in English in which mutation of the gene C9ORF72 was analyzed, and 44 were selected. We described phenotypes of 219 patients. We found 31 different phenotypes. In HCRP, patients with suggestive symptoms were selected to collect blood after informed consent. DNA extraction from the blood was done by an automated way in Genomic Medical Center in HCRP. Amplification of fragments of interest was obtained by polymerase chain reaction (PCR) and the qualitative method Repeat-primed PCR (RP-PCR). We identified 17 patients with mutation and their clinical manifestations were described. Six phenotypes were described including ALS, ALS-FTD, behavioral variant FTD, progressive aphasia associated with ALS, schizophrenia and Primary Lateral Sclerosis. We conclude variability of initial clinical presentation of patients with mutation is extensive. It is not known why this mutation manifests itself in different ways. Its important to understand how repeat expansion size causes distinct diseases, and to achieve a greater knowledge of the gene penetrance for genetic counseling of affected families.

La catégorisation est un ensemble d’opérations mentales qui permettent de classer les objets et les évènements. C’est un processus crucial pour de nombreuses situations, telles que la survie dans le monde animal, l’apprentissage chez l’enfant, ou encore le raisonnement abstrait et la résolution de problèmes. Les patients ayant des lésions du cortex préfrontal présentent des difficultés pour les tâches de catégorisation, et l’existence de ces difficultés est corrélée au handicap fonctionnel de ces patients. Dans une première partie, nous avons mis au point une tâche de catégorisation adaptée pour l’utilisation chez le patient, intitulée SimiCat. A l’aide de cette tâche, nous avons précisé les difficultés de catégorisation des patients et montré que les erreurs de type différenciations sont spécifiques des patients frontaux. La tâche SimiCat présente une très bonne valeur diagnostique pour distinguer les patients ayant une démence fronto-temporale de ceux ayant une maladie d’Alzheimer. Dans une deuxième partie, nous avons utilisé l’IRM fonctionnelle pour préciser les bases cérébrales de deux processus clés pour la catégorisation : l’abstraction et la détection de similitudes. Nous avons montré que l’abstraction repose sur le cortex préfrontal dorsolatéral gauche, alors que la détection de similitudes repose sur le cortex préfrontal ventrolatéral bilatéral. A l’aide de la morphométrie basée sur le voxel, nous avons montré que la variabilité des performances de catégorisation des sujets sains était corrélée au volume de la portion antérieure du gyrus temporal moyen et inférieur droit, avec un gradient postéro-antérieur selon le niveau d’abstraction de la catégorisation. Dans une troisième partie, nous avons mis au point une tâche de double amorçage sémantique que nous utiliserons pour étudier les processus de catégorisation automatique chez les patients ayant des lésions frontales et temporales. A partir de ces résultats, nous proposons un modèle d’organisation cérébrale pour la catégorisation, reposant sur les régions temporales antérieures, le cortex préfrontal ventrolatéral bilatéral et dorsolatéral gauche. Nos résultats permettent également de mieux comprendre les déficits de catégorisation des patients, ce qui permettra d’adapter leur prise en charge diagnostique et thérapeutique. / Categorization is a set of mental processes that allow classifying objects and events. It is crucial in various contexts such as survival in animals, concept learning in children, abstract reasoning and problem solving. Patients with brain lesions involving the prefrontal cortex are impaired in categorization tasks. Categorization impairment correlates with functional autonomy in dementia. In the first part, we have developed a task, named SimiCat that we designed in order to assess categorization abilities in patients. With the help of this task, we showed that differentiation errors are specific of frontal patients. The SimiCat task has a good diagnostic value to distinguish behavior variant Frontotemporal dementia from Alzheimer disease.In the second part, we assessed the brain correlates of categorization. With functional MRI, we showed that abstraction involves the left dorsolateral prefrontal cortex, while similarity detection involves bilateral ventrolateral prefrontal cortex. With voxel-based morphometry we showed that variability in categorization performances correlates with the volume of the right anterior temporal lobe, with a caudo-rostral gradient according to abstraction. In the third part, we developed a double priming task that we will use to assess automatic categorization processes in patients with temporal and frontal lesions. Based on these results, we propose a model of brain organization for categorization. This model involves both anterior temporal lobes, as well as bilateral ventrolateral and left dorsolateral prefrontal cortices. Our results also contribute to a better understanding and management of patients suffering from categorization deficits.

No description available.

La dégénérescence frontotemporale est une pathologie rare, plaçant au premier plan les désordres comportementaux. Après analyse des troubles psycho-comportementaux et de leurs méthodes actuelles d’évaluation, nous avons élaboré et validé un nouvel outil, appelé DAPHNE (pour Desinhibition-Apathie-Persévérations-Hyeroralité-Négligence-Empathie) spécialement conçu pour dépister et quantifier la sévérité et la progression des troubles du comportement dans la variante frontale de dégénérescence frontotemporale (vfDFT), en pratique clinique courante. Cette validation a été effectuée de manière prospective, auprès d’une population de patients présentant une vfDFT suivis pendant 2 ans et également d’une population contrôle afin d’établir sa spécificité. DAPHNE, adaptée des critères révisés de vfDFT, présente d’excellentes caractéristiques psychométriques. Explorant six domaines et dix symptômes comportementaux, avec un système de cotation innovant en 5 points, elle permet à la fois le screening mais également une appréciation quantitative et une aide au diagnostic. Parallèlement à cela, nous avons étudié les liens entre les différents troubles psycho-comportementaux, les fonctions cognitives proprement dites et la cognition sociale chez les patients vfDFT. Plus particulièrement, nous nous sommes intéressés à l’évaluation des troubles émotionnels des patients DFT. À l’aide d’une tâche originale TABEAU, portant sur l’étude de la sensibilité esthétique des patients DFT, nous avons observé des liens entre émotion et troubles du comportement (trouble de l’identification de certaines émotions et émoussement affectif etc.). Si le jugement esthétique est préservé en apparence, le patient est en difficulté sur le plan des processus cognitifs du fait de difficultés d’abstraction et en difficulté sur le plan des processus émotionnels. Ce travail montre quel spectateur est le patient DFT vis à vis de l’art et vient compléter les données de la littérature qui portaient jusque-là sur l’expression artistique. Ce type d’approche cognitive permet donc d’avancer dans la compréhension des interactions entre émotions et troubles du comportement, qui font toute la singularité de cette maladie. Pris dans leur ensemble, nos résultats soulignent l’intérêt majeur de l’étude fine du comportement en pratique quotidienne. À l’ère des biomarqueurs, la clinique garde une place de choix pour le diagnostic et la compréhension des maladies neurodégénératives. / Frontotemporal degeneration is a rare disease with early decline in social behavior and personal conduct. We have first presented behavioral disorders and their current evaluation methods. We developed and validated then a new tool, named DAPHNE (Disinhibition-Apathy-Perseverations-Hyerorality-Neglect-Empathy) specially designed to detect and quantify the severity and the progression of behavioral disorders in the behavioral variant of frontotemporal dementia (bvFTD), in clinical practice. This validation was performed prospectively, in patients with bvFTD with a follow-up of 2 years and also in AD, progressive supranuclear palsy and bipolar patients with cognitive disorders, in order to establish the specificity of this scale. DAPHNE, adapted from revised criteria of bvFTD, has excellent psychometric characteristics. Exploring six areas and ten behavioral symptoms, with an innovative scoring system in 5 points, it enables both the screening but also a quantitative assessment and a diagnostic support.As a second part of our works, we studied the links between the various psycho-behavioral disorders, cognitive functions and social cognition in bvFTD patients. Specifically, we focused on emotion assessment of FTD patients. Using an original task entitled TABEAU, based on the study of aesthetic sensibility of FTD patients, we observed the links between emotions and behavior disorders (such as trouble identifying certain emotions or emotional blunting). The aesthetic judgment seemed preserved. But the patient is in trouble in terms of cognitive processes due to abstraction problems and difficulties with emotional processes. This work shows what type of viewer is the FTD patient in front of a piece of art. It adds to the literature data that were previously based only on artistic expression. This cognitive approach improves the understanding of interactions between emotions and behavior disorders which make the singularity of this disease.Taken together, our results highlight the major interest of the detailed assessment of behavior in daily practice. In biomarkers’ era, clinical practice remains central in diagnosing and understanding of neurodegenerative diseases.